Arakoda (tafenoquine; 60 Degrees Pharmaceuticals) has been made available in the US for the prevention of malaria in patients aged ≥18 years.
Arakoda, an 8-aminoquinolone antimalarial, is active against all stages of Plasmodium species. It is intended for dosing as follows: a loading regimen taken daily for 3 days prior to travel to an endemic area, a weekly dose while in the malarious area, then a one-time terminal prophylaxis dose in the week following exit from the malarious area. Arakoda can be administered for up to 6 months of continuous dosing; patients should be advised that they need to complete the full course including the loading dose and the terminal dose.
Due to the risk of hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, G6PD testing must be performed before prescribing. In addition, pregnancy testing is recommended for females of reproductive potential prior to initiating treatment.
Arakoda is supplied as 100mg tablets; each carton contains 16 tablets (2 blister cards containing 8 tablets each). The product is commercially available in select retail pharmacies and pharmaceutical wholesalers.
Guidance on the use of tafenoquine for malaria prevention was recently published in the Centers for Disease Control and Prevention’s Morbidity and Mortality Weekly Report.
For more information visit 60degreespharma.com.
This article originally appeared on MPR